A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
← catalyst calendarSponsored by Protagonist Therapeutics, Inc. (industry) · PTGX — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
293actual
Sites
184
Countries
Australia, Austria, Belgium +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-01 | actual | When the study began enrolling |
| Primary completion | 2025-02-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Polycythemia Vera
Interventions
- Drug: Placebo
- Drug: Rusfertide
Primary outcome
what the primary-completion date above is the date OFProportion of subjects achieving a response who receive rusfertide compared to placebo.
measured Week 20 through Week 32
Permalink · PTGX's whole pipeline · Catalyst calendar · Every registered study · What changed